SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Multi-omics characterization of immune triggers in Moyamoya disease

The project investigates the link between immune responses to infections and the onset of Moyamoya disease in RNF213 mutation carriers using a multi-omics approach to uncover underlying mechanisms.

Subsidie
€ 1.981.593
2023

Projectdetails

Introduction

This project aims to characterize a recently discovered link between a rare genetic disorder of the brain, called Moyamoya disease (MMD), and the cellular immune response against microbial infections. MMD is characterized by a progressive occlusion of arteries at the base of the brain leading to stroke. Mutations in Ring Finger Protein 213 (RNF213) represent the most common genetic cause of MMD; however, it is suggested that environmental stimuli are needed to trigger disease onset in genetic carriers.

Discovery of RNF213

Intriguingly, we recently discovered RNF213 as a novel antibacterial protein that can target intracellular Listeria (Gram+), providing strong protection to Listeria both in vitro and in vivo.

Interaction with Other Pathogens

Similarly, RNF213 can bind intracellular Salmonella (Gram-), mediating its ubiquitin-dependent degradation. Moreover, we also identified RNF213 as a cellular sensor for proteins modified by ISG15 (ISGylated proteins), a ubiquitin-like modification of the immune system induced by interferon.

Implications of Findings

These observations not only uncover RNF213 as a novel key antimicrobial protein, but they also suggest an important role for the immune system in triggering MMD.

Hypothesis

MULTIMOYA starts from the hypothesis that dysregulated immune responses to infections might trigger MMD disease onset in patients carrying mutations in RNF213.

Research Approach

To investigate this hypothesis, we will:

  1. Determine whether MMD patient-derived immune cells respond differently to:

    • Interferon
    • LPS
    • Bacterial infection
  2. Map altered pathways using a multi-omics approach, combining:

    • Genomics
    • Transcriptomics
    • Proteomics
    • (Tracer) metabolomics data

Validation of Results

Results will be validated by biochemical and imaging analysis in relevant patient-derived/like cellular models as well as in mouse models of MMD that we will establish.

Conclusion

Together, these experiments will provide unprecedented insight into MMD-related immune responses and fundamental processes that link cellular immunity with vascular disease.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.981.593
Totale projectbegroting€ 1.981.593

Tijdlijn

Startdatum1-8-2023
Einddatum31-7-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VIB VZWpenvoerder

Land(en)

Belgium

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Unravelling the role of neuronal antibodies and innate immunity partnership in human autoimmune encephalitis

ImmuBRAIN aims to uncover the interplay between adaptive and innate immune responses in NMDAR encephalitis to develop novel therapies that enhance recovery and patient outcomes.

ERC Starting...€ 1.499.625
2025
Details

Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs

MIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects.

ERC Consolid...€ 1.933.148
2025
Details

Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?

This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets.

ERC Starting...€ 1.498.610
2024
Details

The function of B cells in myocardial infarction-accelerated atherosclerosis

This project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease.

ERC Starting...€ 1.475.638
2023
Details

Unveiling the functional outcome of single nucleotide polymorphisms and variants in oligodendroglia in multiple sclerosis

This project aims to explore the active role of oligodendroglia in multiple sclerosis by analyzing SNPs/variants through single-cell omics and CRISPR editing to identify therapeutic targets.

ERC Advanced...€ 3.182.846
2024
Details
ERC Starting...

Unravelling the role of neuronal antibodies and innate immunity partnership in human autoimmune encephalitis

ImmuBRAIN aims to uncover the interplay between adaptive and innate immune responses in NMDAR encephalitis to develop novel therapies that enhance recovery and patient outcomes.

ERC Starting Grant
€ 1.499.625
2025
Details
ERC Consolid...

Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs

MIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects.

ERC Consolidator Grant
€ 1.933.148
2025
Details
ERC Starting...

Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?

This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets.

ERC Starting Grant
€ 1.498.610
2024
Details
ERC Starting...

The function of B cells in myocardial infarction-accelerated atherosclerosis

This project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease.

ERC Starting Grant
€ 1.475.638
2023
Details
ERC Advanced...

Unveiling the functional outcome of single nucleotide polymorphisms and variants in oligodendroglia in multiple sclerosis

This project aims to explore the active role of oligodendroglia in multiple sclerosis by analyzing SNPs/variants through single-cell omics and CRISPR editing to identify therapeutic targets.

ERC Advanced Grant
€ 3.182.846
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.

EIC Pathfinder€ 3.999.840
2023
Details

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions

CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.

EIC Pathfinder€ 4.349.410
2023
Details
EIC Pathfinder

A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.

EIC Pathfinder
€ 3.999.840
2023
Details
EIC Pathfinder

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions

CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.

EIC Pathfinder
€ 4.349.410
2023
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.